In a previous study, we highlighted glucose transporter 1 (GLUT1) as a stage-independent prognostic biomarker for ACC, determined by assessing GLUT1 expression in tissue sections from ACC patients [24]. This evidence concerns the gene SLC2A1 and adrenal cortex carcinoma.